zolpidem has been researched along with Depression in 25 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of paroxetine with or without zolpidem on depression with insomnia." | 9.12 | [Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study]. ( Chen, ZQ; Ji, JL; Liu, WJ; Mei, QY; Pan, JY; Tao, M; Wang, YP; Wei, J; Zhang, N; Zhao, ZX; Zheng, AL, 2007) |
| "These cases, plus prior case reports, suggest that a pharmacodynamic interaction between serotonin reuptake inhibition and zolpidem may lead to prolonged zolpidem-associated hallucinations in susceptible individuals." | 8.80 | Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. ( Burgess, JL; Elko, CJ; Robertson, WO, 1998) |
| "The REST-IT study found the addition of zolpidem-controlled release (CR) provided a significant reduction in observer-rated measurement of suicidal ideation (the Columbia Suicide Severity Rating Scale) in 103 depressed outpatients with insomnia and suicidal ideation, but without significant change in a self-report measure of suicidal ideation (the Scale for Suicide Ideation)." | 8.31 | The effect of zolpidem-CR on the suicide item of the Hamilton Rating Scale for Depression in outpatients with depression, insomnia and suicidal ideation: Lessons learned. ( Benca, RM; Dzurny, TN; Krystal, AD; Looney, SW; McCall, WV; McCloud, LL; Mercado, K; Rosenquist, PB, 2023) |
| "A retrospective cohort study was conducted using IBM MarketScan Commercial and Medicare Supplemental Databases to identify adults with: (1) ≥1 ICD-9/ICD-10 code for depression; (2) ≥1 commonly prescribed medication for insomnia (zolpidem immediate release [IR], zolpidem extended release [ER], trazodone, or benzodiazepines); and (3) ≥12 months of eligibility before and after initiating insomnia medication." | 8.12 | Incremental health care resource use and costs among adult patients with depression and treated for insomnia with zolpidem, trazodone, or benzodiazepines. ( Amari, DT; Frech, F; Gor, D; Juday, TR; Malhotra, M; Wickwire, EM, 2022) |
| "To investigate the association between zolpidem prescription and suicide attempts in people with depression." | 7.96 | Risks of suicide attempts after prescription of zolpidem in people with depression: a nationwide population study in South Korea. ( Choi, KW; Fava, M; Jeon, HJ; Kim, H; Kim, Y; Lee, H; Lee, U; Mischoulon, D; Myung, W; Na, EJ; Shin, MH, 2020) |
| "We examined the association of insomnia, eveningness, seasonality, and rhythmicity with suicidal ideation in 103 participants with depression, insomnia, and suicidality within a larger 8-week double-blinded randomized control trial primarily examining whether cautious use of zolpidem extended-release or placebo reduced suicidal ideation." | 5.34 | An exploratory analysis of the association of circadian rhythm dysregulation and insomnia with suicidal ideation over the course of treatment in individuals with depression, insomnia, and suicidal ideation. ( Benca, RM; Dickson, DA; Krystal, AD; McCall, WV; Rosenquist, PB; Rumble, ME, 2020) |
| " Participants were 160 individuals with chronic insomnia who received CBT alone or CBT plus medication (zolpidem) for an initial six-week therapy, followed by an extended six-month therapy." | 5.22 | Cognitive-behavior therapy singly and combined with medication for persistent insomnia: Impact on psychological and daytime functioning. ( Beaulieu-Bonneau, S; Bélanger, L; Guay, B; Ivers, H; Mérette, C; Morin, CM; Sánchez Ortuño, M; Savard, J; Vallières, A, 2016) |
| "To compare the effects of paroxetine with or without zolpidem on depression with insomnia." | 5.12 | [Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study]. ( Chen, ZQ; Ji, JL; Liu, WJ; Mei, QY; Pan, JY; Tao, M; Wang, YP; Wei, J; Zhang, N; Zhao, ZX; Zheng, AL, 2007) |
| "These cases, plus prior case reports, suggest that a pharmacodynamic interaction between serotonin reuptake inhibition and zolpidem may lead to prolonged zolpidem-associated hallucinations in susceptible individuals." | 4.80 | Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. ( Burgess, JL; Elko, CJ; Robertson, WO, 1998) |
| "The REST-IT study found the addition of zolpidem-controlled release (CR) provided a significant reduction in observer-rated measurement of suicidal ideation (the Columbia Suicide Severity Rating Scale) in 103 depressed outpatients with insomnia and suicidal ideation, but without significant change in a self-report measure of suicidal ideation (the Scale for Suicide Ideation)." | 4.31 | The effect of zolpidem-CR on the suicide item of the Hamilton Rating Scale for Depression in outpatients with depression, insomnia and suicidal ideation: Lessons learned. ( Benca, RM; Dzurny, TN; Krystal, AD; Looney, SW; McCall, WV; McCloud, LL; Mercado, K; Rosenquist, PB, 2023) |
| "A retrospective cohort study was conducted using IBM MarketScan Commercial and Medicare Supplemental Databases to identify adults with: (1) ≥1 ICD-9/ICD-10 code for depression; (2) ≥1 commonly prescribed medication for insomnia (zolpidem immediate release [IR], zolpidem extended release [ER], trazodone, or benzodiazepines); and (3) ≥12 months of eligibility before and after initiating insomnia medication." | 4.12 | Incremental health care resource use and costs among adult patients with depression and treated for insomnia with zolpidem, trazodone, or benzodiazepines. ( Amari, DT; Frech, F; Gor, D; Juday, TR; Malhotra, M; Wickwire, EM, 2022) |
| " Retrospectively, both subjects suffered from psychiatric disorders and in case 2, the subject was treated for depression with doxepin." | 3.81 | Sleep self-intoxication and sleep driving as rare zolpidem-induced complex behaviour. ( Paulke, A; Toennes, SW; Wunder, C, 2015) |
| "Zolpidem use might unmask preclinical Parkinson's disease, especially in patients with depression." | 3.81 | Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study. ( Huang, HC; Kao, CH; Lin, KH; Lu, MK; Muo, CH; Sung, FC; Tsai, CH, 2015) |
| "A 47-year-old white man with a history of bipolar disorder was being maintained on citalopram 40 mg once daily and zolpidem 5 mg at bedtime." | 3.72 | Somnambulism due to probable interaction of valproic acid and zolpidem. ( Bhatia, SC; Petty, F; Ramaswamy, S; Sattar, SP, 2003) |
| "Zolpidem (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the death of a 39-year-old obese male who was being treated for depression and insomnia." | 3.69 | Zolpidem tissue concentrations in a multiple drug related death involving Ambien. ( Benson, PA; Macapagal, EC; Meeker, JE; Som, CW, 1995) |
| "Past modafinil use was reported by 2." | 2.74 | Modafinil and zolpidem use by emergency medicine residents. ( Ankel, FK; Asplin, BR; Flottemesch, TJ; Ling, LJ; Mason, EJ; McBeth, BD; McNamara, RM, 2009) |
| "Zolpidem was well tolerated with no withdrawal symptoms during the second 7-day placebo treatment period." | 2.67 | A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. ( Coquelin, JP; Curson, H; Shaw, SH, 1992) |
| "Diagnosis of insomnia is challenging because there can be many different causes and the clinical picture can be blurred by the presence of other psychiatric illnesses." | 2.40 | Pathophysiology and management of insomnia during depression. ( Kupfer, DJ, 1999) |
| "Nocturnal eating disorders are more common than previously thought." | 1.34 | Zolpidem and amnestic sleep related eating disorder. ( Najjar, M, 2007) |
| "To reduce withdrawal symptoms long-acting benzodiazepines were given to both patients." | 1.30 | [Dependency of non-benzodiazepine hypnotics. Two case reports]. ( Antonijevic, IA; Sonntag, A; Steiger, A; Ströhle, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (28.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wickwire, EM | 1 |
| Amari, DT | 1 |
| Juday, TR | 1 |
| Frech, F | 1 |
| Gor, D | 1 |
| Malhotra, M | 1 |
| McCall, WV | 2 |
| Mercado, K | 1 |
| Dzurny, TN | 1 |
| McCloud, LL | 1 |
| Krystal, AD | 2 |
| Benca, RM | 2 |
| Rosenquist, PB | 2 |
| Looney, SW | 1 |
| Kim, H | 1 |
| Kim, Y | 1 |
| Myung, W | 1 |
| Fava, M | 1 |
| Mischoulon, D | 1 |
| Lee, U | 1 |
| Lee, H | 1 |
| Na, EJ | 1 |
| Choi, KW | 1 |
| Shin, MH | 1 |
| Jeon, HJ | 1 |
| Schreiber, S | 1 |
| Pick, CG | 1 |
| Rumble, ME | 1 |
| Dickson, DA | 1 |
| Jonsson, BH | 1 |
| Moore, TJ | 1 |
| Mattison, DR | 1 |
| El Zahaf, NA | 1 |
| Salem Elhwuegi, A | 1 |
| Paulke, A | 1 |
| Wunder, C | 1 |
| Toennes, SW | 1 |
| Huang, HC | 1 |
| Tsai, CH | 1 |
| Muo, CH | 1 |
| Lin, KH | 1 |
| Lu, MK | 1 |
| Sung, FC | 1 |
| Kao, CH | 1 |
| Morin, CM | 1 |
| Beaulieu-Bonneau, S | 1 |
| Bélanger, L | 1 |
| Ivers, H | 1 |
| Sánchez Ortuño, M | 1 |
| Vallières, A | 1 |
| Savard, J | 1 |
| Guay, B | 1 |
| Mérette, C | 1 |
| McBeth, BD | 1 |
| McNamara, RM | 1 |
| Ankel, FK | 1 |
| Mason, EJ | 1 |
| Ling, LJ | 1 |
| Flottemesch, TJ | 1 |
| Asplin, BR | 1 |
| Allison, KC | 1 |
| Tarves, EP | 1 |
| Sattar, SP | 1 |
| Ramaswamy, S | 1 |
| Bhatia, SC | 1 |
| Petty, F | 1 |
| Cotroneo, A | 1 |
| Gareri, P | 1 |
| Nicoletti, N | 1 |
| Lacava, R | 1 |
| Grassone, D | 1 |
| Maina, E | 1 |
| De Sarro, G | 1 |
| Cabodi, S | 1 |
| Ji, JL | 1 |
| Liu, WJ | 1 |
| Zhang, N | 1 |
| Chen, ZQ | 1 |
| Zheng, AL | 1 |
| Mei, QY | 1 |
| Pan, JY | 1 |
| Zhao, ZX | 1 |
| Tao, M | 1 |
| Wang, YP | 1 |
| Wei, J | 1 |
| Winkelmayer, WC | 1 |
| Mehta, J | 1 |
| Wang, PS | 1 |
| Najjar, M | 1 |
| Meyer, C | 1 |
| Meeker, JE | 1 |
| Som, CW | 1 |
| Macapagal, EC | 1 |
| Benson, PA | 1 |
| Elko, CJ | 1 |
| Burgess, JL | 1 |
| Robertson, WO | 1 |
| Ströhle, A | 1 |
| Antonijevic, IA | 1 |
| Steiger, A | 1 |
| Sonntag, A | 1 |
| Kupfer, DJ | 1 |
| Musshoff, F | 1 |
| Schmidt, P | 1 |
| Madea, B | 1 |
| Shaw, SH | 1 |
| Curson, H | 1 |
| Coquelin, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reducing Suicidal Ideation Through Insomnia Treatment[NCT01689909] | Phase 4 | 103 participants (Actual) | Interventional | 2012-12-06 | Completed | ||
| Behavioral and Pharmacological Treatment for Insomnia[NCT00042146] | Phase 4 | 160 participants | Interventional | 2001-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"This device measures arm motion over time, reported as average actigraphic activity Level. The scale is reported as a continuous measure ranging from 0-200, and reported as the average score for each hour for all 24-hours of the day. Higher score represent greater c=activity at that point in time" (NCT01689909)
Timeframe: 8 weeks of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Scale for Suicide Ideation Score Greater Than or Equal to 6 | 150 |
| Scale for Suicide Ideation Score Less Than 6 | 170 |
This is one of the subscales of the Basis 32. It is self-administered. This subscale has 7 items, each scored 0-4. The totals score is an average of the scores of these 7 items. Higher scores indicate more difficulty with daily living and role functioning. (NCT01689909)
Timeframe: 8 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Zolpidem-CR | 1.51 |
| Placebo | 1.60 |
The Beck Hopelessness Scale is self administered and has 20 'true/false' choices. Some items are reversed scored. The range of scores for the total is 0-20, with higher scores indicating greater hopelessness (NCT01689909)
Timeframe: 8 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Zolpidem-CR | 9.40 |
| Placebo | 9.63 |
"The suicide ideation scale of the C-SSRS is rated 0-5, with 0 meaning no suicidal ideation, 1 meaning a wish t be dead, 2 meaning non-specific active suicidal thoughts, 3 meaning active suicidal ideation with any methods but no plan or intent, 4 meaning active suicidal ideation with some intent but no specific plan, and 5 meaning active suicidal ideation with intent and a specific plan" (NCT01689909)
Timeframe: 8 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Zolpidem-CR | 0.5447 |
| Placebo | 0.8067 |
This self-rated scale has 5 items, with asymmetric weighting of each item. The range of the total score is 0-37, with higher scores indicating worse nightmares (NCT01689909)
Timeframe: 8 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Zolpidem-CR | 5.74 |
| Placebo | 6.44 |
The Dysfunctional Beliefs and Attitudes About Sleep scale has 16 items and is self administered. Each item is scored 0-10. The total score is an average of the scores of the 16 items. Hence the range of the total score is also 0-10, with higher scores indicating greater dysfunctional beliefs about sleep (NCT01689909)
Timeframe: 8 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Zolpidem-CR | 6.03 |
| Placebo | 6.07 |
This version of the Hamilton Rating Scale for Depression uses 24 items, with a possible total score ranging from 0-74, with higher scores indicating worse depression (NCT01689909)
Timeframe: 8 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Zolpidem-CR | 14.93 |
| Placebo | 15.89 |
The Insomnia Severity Index is self rated. It has 7 items, each scored 0-4. Therefore the range of scores is 0-28, with higher scores indicating worse insomnia (NCT01689909)
Timeframe: 8 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Zolpidem-CR | 11.28 |
| Placebo | 13.72 |
This is the total score for the Scale for Suicide Ideation. It has 19 items, each scored 0-2, for a maximum of 38 points. Higher scores indicate worse suicidal ideation (NCT01689909)
Timeframe: Over 8 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Zolpidem-CR | 4.66 |
| Placebo | 5.25 |
2 reviews available for zolpidem and Depression
| Article | Year |
|---|---|
Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction.
Topics: Adolescent; Adult; Antidepressive Agents; Depression; Drug Interactions; Drug Therapy, Combination; | 1998 |
Pathophysiology and management of insomnia during depression.
Topics: Anti-Anxiety Agents; Benzodiazepines; Brain; Chronic Disease; Depression; Female; Humans; Hypnotics | 1999 |
5 trials available for zolpidem and Depression
| Article | Year |
|---|---|
An exploratory analysis of the association of circadian rhythm dysregulation and insomnia with suicidal ideation over the course of treatment in individuals with depression, insomnia, and suicidal ideation.
Topics: Circadian Rhythm; Depression; Humans; Sleep Initiation and Maintenance Disorders; Suicidal Ideation; | 2020 |
Cognitive-behavior therapy singly and combined with medication for persistent insomnia: Impact on psychological and daytime functioning.
Topics: Activities of Daily Living; Adult; Aged; Anxiety; Cognitive Behavioral Therapy; Combined Modality Th | 2016 |
Modafinil and zolpidem use by emergency medicine residents.
Topics: Adult; Akathisia, Drug-Induced; Amnesia; Anorexia; Benzhydryl Compounds; Central Nervous System Stim | 2009 |
[Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study].
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Therapy, Combination; Female; Humans; Hyp | 2007 |
A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients.
Topics: Aged; Dementia; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; H | 1992 |
18 other studies available for zolpidem and Depression
| Article | Year |
|---|---|
Incremental health care resource use and costs among adult patients with depression and treated for insomnia with zolpidem, trazodone, or benzodiazepines.
Topics: Adult; Aged; Benzodiazepines; Delivery of Health Care; Depression; Female; Health Care Costs; Humans | 2022 |
The effect of zolpidem-CR on the suicide item of the Hamilton Rating Scale for Depression in outpatients with depression, insomnia and suicidal ideation: Lessons learned.
Topics: Depression; Humans; Outpatients; Psychiatric Status Rating Scales; Sleep Initiation and Maintenance | 2023 |
Risks of suicide attempts after prescription of zolpidem in people with depression: a nationwide population study in South Korea.
Topics: Depression; Humans; Prescriptions; Republic of Korea; Risk Factors; Suicide, Attempted; Zolpidem | 2020 |
Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep?
Topics: Analgesics; Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Disease Models, Animal; | 2020 |
Nicotinic Acid Long-Term Effectiveness in a Patient with Bipolar Type II Disorder: A Case of Vitamin Dependency.
Topics: Aged; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Depression; Dose-Response Relationsh | 2018 |
Assessment of Patterns of Potentially Unsafe Use of Zolpidem.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Depression; Dose-Response Relationship, Drug; Drug-Relat | 2018 |
The effect of GABAmimetics on the duration of immobility in the forced swim test in albino mice.
Topics: Alprazolam; Animals; Depression; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; | 2014 |
Sleep self-intoxication and sleep driving as rare zolpidem-induced complex behaviour.
Topics: Adult; Amnesia; Antidepressive Agents, Tricyclic; Automobile Driving; Depression; Doxepin; Drug Over | 2015 |
Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzodiazepines; Comorbidity; Depression; Female; Humans | 2015 |
Treatment of night eating syndrome.
Topics: Anorexia; Behavior Therapy; Circadian Rhythm; Cognitive Behavioral Therapy; Depression; Diet Records | 2011 |
Somnambulism due to probable interaction of valproic acid and zolpidem.
Topics: Bipolar Disorder; Citalopram; Depression; Drug Interactions; Drug Therapy, Combination; Humans; Male | 2003 |
Effectiveness and safety of hypnotic drugs in the treatment of insomnia in over 70-year old people.
Topics: Aged; Cognition Disorders; Dementia; Depression; Drug Administration Schedule; Female; Health Status | 2007 |
Benzodiazepine use and mortality of incident dialysis patients in the United States.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Cohort Studies; Depression; Female; Foll | 2007 |
Zolpidem and amnestic sleep related eating disorder.
Topics: Amnesia, Anterograde; Compulsive Behavior; Depression; Feeding and Eating Disorders; Female; Humans; | 2007 |
New drugs. In the realm of the brain.
Topics: Central Nervous System Agents; Depression; Humans; Hypnotics and Sedatives; Migraine Disorders; Paro | 1993 |
Zolpidem tissue concentrations in a multiple drug related death involving Ambien.
Topics: Administration, Oral; Adult; Depression; Drug Overdose; Fatal Outcome; Gas Chromatography-Mass Spect | 1995 |
[Dependency of non-benzodiazepine hypnotics. Two case reports].
Topics: Adult; Azabicyclo Compounds; Benzodiazepines; Depression; Humans; Hypnotics and Sedatives; Male; Mid | 1999 |
Fatality caused by a combined trimipramine-citalopram intoxication.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depression; | 1999 |